Biofrontera Inc. (BFRI) stock

BFRINasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/30

$0.70−0.23 (-24.39%)

Close on Nov 13, 2026Market cap $10.40MP/E –Yield –

Biofrontera price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Biofrontera's price to sales ratio was 0.3× on Nov 11, 2026, against 0.3× a year earlier. Over the last 5 years it ranged from 0.0× to 2.6×, with a median of 0.3×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	0.3×	+0.1
2025	Dec 31, 2025	0.2×	−0.0
2024	Dec 31, 2024	0.2×	+0.1
2023	Dec 29, 2023	0.1×	−0.7
2022	Dec 30, 2022	0.8×	−1.8
2021	Dec 31, 2021	2.6×	–

Where these numbers come from

Parsed from the XBRL in Biofrontera's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Jul 5, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BFRI.

Compare: BFRI vs VRCA · BFRI vs FBIO · BFRI vs DERM · BFRI vs OCUL · BFRI vs SIGA

Revenue growth29.8% · median -9.7%

Operating margin-14.1% · median -42.5%

Net margin-12.7% · median -7.3%

Company	Revenue	Growth
FBIO	$69.99M	+12.3%
DERM	$69.52M	+17.0%
SIGA	$52.36M	-69.6%
OCUL	$50.38M	-9.7%
BFRI	$48.26M	+29.8%
VRCA	$22.89M	-25.7%

Company

Next earnings (est.): Mar 18, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 92
Held by institutions: 18.6%
Auditor: Marcum llp
SEC CIK: 1858685

Advertisement
300 × 250

See a number that looks wrong?